866-997-4948(US-Canada Toll Free)

Wounds - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 186 Pages

Wounds - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wounds - Pipeline Review, H1 2017, provides an overview of the Wounds (Dermatology) pipeline landscape.

Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or fever.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wounds - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Wounds (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 5, 1, 58, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 7 molecules, respectively.

Wounds (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Wounds (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Wounds - Overview 9
Wounds - Therapeutics Development 10
Pipeline Overview 10
Pipeline by Companies 11
Pipeline by Universities/Institutes 16
Products under Development by Companies 18
Products under Development by Universities/Institutes 22
Wounds - Therapeutics Assessment 23
Assessment by Target 23
Assessment by Mechanism of Action 26
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Wounds - Companies Involved in Therapeutics Development 33
AlgiPharma AS 33
Alliance Pharma Plc 33
AmpliPhi Biosciences Corp 33
AndroScience Corp 34
Anterogen Co Ltd 34
Aridis Pharmaceuticals LLC 35
Beech Tree Labs Inc 35
Bio3 Research Srl 35
Biotec Pharmacon ASA 36
Blueberry Therapeutics Ltd 36
Cellphire Inc 36
Chiesi Farmaceutici SpA 37
CorMedix Inc 37
Dermala Inc 38
Destiny Pharma Ltd 38
Escape Therapeutics Inc 38
EyeGene Inc 39
FibroGen Inc 39
Foresee Pharmaceuticals LLC 40
Gene Signal International SA 40
GlaxoSmithKline Plc 40
IC-MedTech Inc 41
Living Cell Technologies Ltd 41
Madam Therapeutics BV 42
miRagen Therapeutics Inc 42
NatureWise Biotech & Medicals Corp 43
Novan Inc 43
Octapharma AG 44
Omeros Corp 44
Osiris Therapeutics Inc 44
Pacific Northwest Biotechnology LLC 45
ProMetic Life Sciences Inc 45
RMB-Research GmbH 46
RXi Pharmaceuticals Corp 46
SomaGenics Inc 47
Stratatech Corp 47
Synedgen Inc 47
Thesan Pharmaceuticals Inc 48
Topadur Pharma AG 48
Traverse Biosciences Inc 48
Tumorend LLC 49
Vascular BioSciences 49
viDA Therapeutics Inc 49
Wounds - Drug Profiles 51
(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile 51
A-3APO - Drug Profile 52
ABSA-01 - Drug Profile 54
AGL-110 - Drug Profile 58
ALLO-ASC - Drug Profile 59
AlloGraf - Drug Profile 61
Antisense RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing - Drug Profile 62
APO-1 - Drug Profile 63
APO-2 - Drug Profile 64
AR-101 - Drug Profile 65
Arginine Butyrate - Drug Profile 66
ARN-077 - Drug Profile 67
ASCJ-9 - Drug Profile 68
AyuV-25 - Drug Profile 70
B-244 - Drug Profile 71
BB-1000 - Drug Profile 73
BDM-I - Drug Profile 74
BTL-slo - Drug Profile 77
CAR Peptide - Drug Profile 79
Cell Therapy for Dermatology and Immunology - Drug Profile 80
CM-101 - Drug Profile 82
CRMD-004 - Drug Profile 83
CTR-2 - Drug Profile 84
daprodustat - Drug Profile 85
DB-2121 - Drug Profile 88
Drug to Antagonize Beta 2 Receptor for Wounds - Drug Profile 89
Drugs to Agonize Hepatocyte Growth Factor Receptor for Wounds - Drug Profile 90
Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile 91
EGS-001 - Drug Profile 92
FG-6874 - Drug Profile 93
FP-025 - Drug Profile 94
G-3KL - Drug Profile 95
Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 96
Gene Therapy to Activate HSP60 for Wounds - Drug Profile 97
GS-156 - Drug Profile 98
Human Growth Factor - Drug Profile 99
hVGF - Drug Profile 100
JM-2 CR - Drug Profile 101
LWnt-3a - Drug Profile 102
MG-53 - Drug Profile 103
MMP-26051 - Drug Profile 105
MMP-26052 - Drug Profile 106
molgramostim - Drug Profile 107
Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile 108
MRG-110 - Drug Profile 109
NBM-67 - Drug Profile 110
ND-336 - Drug Profile 111
NTCELL - Drug Profile 112
Oligomer G for Burn Wounds - Drug Profile 117
OTI-1011 - Drug Profile 118
OTI-1502 - Drug Profile 119
P-148 - Drug Profile 120
Panaecin - Drug Profile 121
Peptides for Wounds - Drug Profile 122
Perlecan - Drug Profile 123
PGF - Drug Profile 125
plasminogen (recombinant) - Drug Profile 126
Polysaccharide for Wounds and Scars - Drug Profile 127
Protein for Hematological Disorders, Dermatology, Shock, Injury, Trauma and Infectious Disease - Drug Profile 128
Protein for Infectious Disease, Wounds and Skin Infections - Drug Profile 129
Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile 130
Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile 131
Recombinant Protein to Activate Fibroblast Growth Factor for Wounds - Drug Profile 132
Recombinant Protein to Agonize FGFR2 for Wounds - Drug Profile 133
Recombinant Protein to Agonize NGFR for Wounds - Drug Profile 134
Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile 135
Recombinant Protein to Target MMP-9 for Wounds - Drug Profile 136
Recombinant Proteins for Diabetic Wound Healing - Drug Profile 137
RT-1740 - Drug Profile 138
SFR-9X0125 - Drug Profile 139
SG-404 - Drug Profile 140
silver sulfadiazine - Drug Profile 141
Small Molecule for MRSA Skin Infection and Wound Healing - Drug Profile 142
Small Molecule to Activate MRTF-A for Wound Healing - Drug Profile 143
Small Molecule to Target LGR6 for Dermatology - Drug Profile 144
Small Molecules for Staphylococcal Infections and Wounds - Drug Profile 145
Small Molecules to Activate iRhom2 for Wound Healing and Oncology - Drug Profile 146
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 147
Soluble Beta Glucan - Drug Profile 148
Statmicoll - Drug Profile 151
Stm Cell Therapy for Chronic Wounds - Drug Profile 152
Synthetic Peptide to Antagonize CD168 for Dermatology, Musculoskeletal, Oncology and Respiratory Disorders - Drug Profile 153
Synthetic Peptides for Bacterial Keratitis and Wounds - Drug Profile 154
Synthetic Peptides for Wound Healing and Neurodegenerative Diseases - Drug Profile 155
Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 156
Thrombosomes - Drug Profile 158
Tolecine - Drug Profile 159
TOPN-53 - Drug Profile 160
TRBN-0224 - Drug Profile 161
TWB-103 - Drug Profile 163
V-2248 - Drug Profile 164
VTI-3000 Series - Drug Profile 165
WH-1 - Drug Profile 166
XF-70 - Drug Profile 167
Wounds - Dormant Projects 168
Wounds - Discontinued Products 173
Wounds - Product Development Milestones 174
Featured News & Press Releases 174
Appendix 179
Methodology 179
Coverage 179
Secondary Research 179
Primary Research 179
Expert Panel Validation 179
Contact Us 179
Disclaimer 180

List of Tables
Number of Products under Development for Wounds, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Wounds - Pipeline by AlgiPharma AS, H1 2017
Wounds - Pipeline by Alliance Pharma Plc, H1 2017
Wounds - Pipeline by AmpliPhi Biosciences Corp, H1 2017
Wounds - Pipeline by AndroScience Corp, H1 2017
Wounds - Pipeline by Anterogen Co Ltd, H1 2017
Wounds - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
Wounds - Pipeline by Beech Tree Labs Inc, H1 2017
Wounds - Pipeline by Bio3 Research Srl, H1 2017
Wounds - Pipeline by Biotec Pharmacon ASA, H1 2017
Wounds - Pipeline by Blueberry Therapeutics Ltd, H1 2017
Wounds - Pipeline by Cellphire Inc, H1 2017
Wounds - Pipeline by Chiesi Farmaceutici SpA, H1 2017
Wounds - Pipeline by CorMedix Inc, H1 2017
Wounds - Pipeline by Dermala Inc, H1 2017
Wounds - Pipeline by Destiny Pharma Ltd, H1 2017
Wounds - Pipeline by Escape Therapeutics Inc, H1 2017
Wounds - Pipeline by EyeGene Inc, H1 2017
Wounds - Pipeline by FibroGen Inc, H1 2017
Wounds - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
Wounds - Pipeline by Gene Signal International SA, H1 2017
Wounds - Pipeline by GlaxoSmithKline Plc, H1 2017
Wounds - Pipeline by IC-MedTech Inc, H1 2017
Wounds - Pipeline by Living Cell Technologies Ltd, H1 2017
Wounds - Pipeline by Madam Therapeutics BV, H1 2017
Wounds - Pipeline by miRagen Therapeutics Inc, H1 2017
Wounds - Pipeline by NatureWise Biotech & Medicals Corp, H1 2017
Wounds - Pipeline by Novan Inc, H1 2017
Wounds - Pipeline by Octapharma AG, H1 2017
Wounds - Pipeline by Omeros Corp, H1 2017
Wounds - Pipeline by Osiris Therapeutics Inc, H1 2017
Wounds - Pipeline by Pacific Northwest Biotechnology LLC, H1 2017
Wounds - Pipeline by ProMetic Life Sciences Inc, H1 2017
Wounds - Pipeline by RMB-Research GmbH, H1 2017
Wounds - Pipeline by RXi Pharmaceuticals Corp, H1 2017
Wounds - Pipeline by SomaGenics Inc, H1 2017
Wounds - Pipeline by Stratatech Corp, H1 2017
Wounds - Pipeline by Synedgen Inc, H1 2017
Wounds - Pipeline by Thesan Pharmaceuticals Inc, H1 2017
Wounds - Pipeline by Topadur Pharma AG, H1 2017
Wounds - Pipeline by Traverse Biosciences Inc, H1 2017
Wounds - Pipeline by Tumorend LLC, H1 2017
Wounds - Pipeline by Vascular BioSciences, H1 2017
Wounds - Pipeline by viDA Therapeutics Inc, H1 2017
Wounds - Dormant Projects, H1 2017
Wounds - Dormant Projects, H1 2017 (Contd..1), H1 2017
Wounds - Dormant Projects, H1 2017 (Contd..2), H1 2017
Wounds - Dormant Projects, H1 2017 (Contd..3), H1 2017
Wounds - Dormant Projects, H1 2017 (Contd..4), H1 2017
Wounds - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Wounds, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *